MAETZOLD DEREK J sold $76K of CSTL (indirect holdings)

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 m

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.